Patents by Inventor Nicolas Stransky

Nicolas Stransky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RAF1 FUSIONS
    Publication number: 20170137889
    Abstract: The invention provides to RAF1 gene fusions, RAF1 fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with RAF1 fusions, such as conditions mediated by aberrant RAF1 expression or activity, or overexpression of RAF1.
    Type: Application
    Filed: June 10, 2015
    Publication date: May 18, 2017
    Applicant: BLUEPRINT MEDICINES CORPORATION
    Inventors: Nicolas Stransky, Joseph L. Kim
  • PKN1 FUSIONS
    Publication number: 20170114417
    Abstract: The invention provides to PKN1 gene fusions, PKN1 fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with PKN1 fusions, such as conditions mediated by aberrant PKN1 expression or activity, or over expression of PKN1.
    Type: Application
    Filed: June 10, 2015
    Publication date: April 27, 2017
    Applicant: BLUEPRINT MEDICINES CORPORATION
    Inventors: Nicolas Stransky, Joseph L. Kim
  • MET FUSIONS
    Publication number: 20170044621
    Abstract: The invention provides MET gene fusions. MET fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with MET fusions, such as conditions mediated by aberrant MET expression or activity or overexpression of MET.
    Type: Application
    Filed: April 17, 2015
    Publication date: February 16, 2017
    Applicant: BLUEPRINT MEDICINES CORPORATION
    Inventors: Ehan G. Cerami, Christoph Lengauer, Nicolas Stransky
  • PIK3CA FUSIONS
    Publication number: 20170044622
    Abstract: The invention provides PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) gene fusions, and fragments of those gene fusions. The invention further provides methods of diagnosing and treating diseases or disorders associated with PIK3CA fusions, such as conditions mediated by PIK3CA aberrant expression or activity, or overexpression of PIK3CA.
    Type: Application
    Filed: April 17, 2015
    Publication date: February 16, 2017
    Applicant: BLUEPRINT MEDICINES CORPORATION
    Inventors: Ethan G. Cerami, Christoph Lengauer, Nicolas Stransky
  • NTRK2 FUSIONS
    Publication number: 20160272725
    Abstract: The invention provides to NTRK (“Neurotrophic Tyrosine Receptor Kinase) gene fusions, NTRK. fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with NTRK fusions, such as conditions mediated by aberrant NTRK expression or activity, or overexpression of NTRK.
    Type: Application
    Filed: July 30, 2014
    Publication date: September 22, 2016
    Inventors: Nicolas STRANSKY, Ethan G. CERAMI, Christoph LENGAUER
  • PIK3C2G FUSIONS
    Publication number: 20160251446
    Abstract: The invention provides to PIK3C2G (phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 gamma) gene fusions and PIK3C2G fusion proteins. The invention further provides methods of diagnosing and treating diseases or disorders associated with PK3C2G fusions, such as conditions mediated by aberrant PIK3C2G expression or activity, or conditions associated with overexpression of PIK.3C2G.
    Type: Application
    Filed: July 30, 2014
    Publication date: September 1, 2016
    Inventors: Nicolas STRANSKY, Ethan G. CERAMI, Joseph L. KIM, Christoph LENGAUER
  • Tyrosine kinase receptor TYRO3 as a therapeutic target in the treatment of cancer
    Patent number: 9233144
    Abstract: The present invention concerns new methods for treating cancer by using TYRO3 inhibitors and methods for identifying new molecules of interest for treating cancer.
    Type: Grant
    Filed: September 18, 2009
    Date of Patent: January 12, 2016
    Assignees: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, UNIVERSITE PARIS-EST CRETEIL VAL DE MARNE
    Inventors: Isabelle Bernard-Pierrot, Francois Radvanyi, Yves Allory, Nicolas Stransky
  • METHOD FOR PREDICTING THE SENSITIVITY OF A TUMOR TO AN EPIGENETIC TREATMENT
    Publication number: 20120282167
    Abstract: The present invention provides a method for determining the RES phenotype in a tumor. The present invention further provides a method for predicting the sensitivity of a tumor to an epigenetic treatment, the method comprising determining the RES phenotype in said tumor, the presence of the RES phenotype in a tumor being indicative of a tumor sensitive to an epigenetic therapy. The present invention also provides a method for diagnosing an aggressive tumor and for selecting a patient affected with a tumor for an epigenetic therapy.
    Type: Application
    Filed: August 9, 2010
    Publication date: November 8, 2012
    Applicants: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, UNIVERSITE PARIS-EST CRETEIL VAL DE MARNE, UNIVERSITE PARIS-SUD 11
    Inventors: Céline Vallot, Francois Radvanyi, Nicolas Stransky, Yves Allory
  • TYROSINE KINASE RECEPTOR TYRO3 AS A THERAPEUTIC TARGET IN THE TREATMENT OF CANCER
    Publication number: 20120034167
    Abstract: The present invention concerns new methods for treating cancer by using TYRO3 inhibitors and methods for identifying new molecules of interest for treating cancer.
    Type: Application
    Filed: September 18, 2009
    Publication date: February 9, 2012
    Applicants: INSTITUT CURIE, UNIVERSITE PARIS-EST CRETEIL VAL DE MARNE, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Isabelle Bernard-Pierrot, Francois Radvanyi, Yves Allory, Nicolas Stransky